AMYL THERAPEUTICS - Key Persons

Job Titles:

• Chief Executive Officer
• Chief Medical Officer
• Founder

Pierre has a large experience in development of vaccines, immunotherapeutics and biologicals. He held various positions and has led complex developments at GSK vaccines and in several Biotech companies. Pierre Vandepapelière, M.D.,PhD has a large experience in development of vaccines, immunotherapeutics and biologicals. He held various positions and has led complex developments at GSK vaccines and in several Biotech companies. As CEO and CMO, he transformed Imcyse, a biotech company developing active specific immunotherapeutics to treat and to prevent auto immune diseases, into a rapidly growing Biotech company. Before he was head of early clinical research at GlaxoSmithKline Biologicals and has been involved in the development of vaccines for tuberculosis, HIV, malaria, Hepatitis C, Herpes zoster (Shingrix) and Streptococcus pneumoniae in the elderly, and of therapeutic vaccines for hepatitis B, human papilloma virus and herpes simplex. Pierre also spent 7 years as head of development of immunotherapeutics for auto immune diseases, primarily lupus, at Neovacs, Paris, and as consultant to implement phase IIb programs at Genticel and Abivax. He graduated in Medicine at the Catholic University of Louvain, in Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium and holds a PhD from the University of Gent.

Job Titles:

• Chairman
• Founder
• Investor for Novartis Venture Funds
• Kaufmann Fellow

Florent Gros has has held various leadership positions in venture, intellectual property and business transactions at Nestlé, Pasteur Merieux Connaught and Novartis in Switzerland, Europe and North America. Florent has been an active investor for Novartis Venture Funds, seeding companies, serving as director and advisor, sometimes serving as ad. interim CEO, for biotech and medtech companies such as Adicet Bio, Anokion, Binx Health, Covagen, Evolva, Gensight Biologics, Inflazome, Merus, Okairos, Oculis, Vivet Therapeutics. In 2019, Florent founded and led as CEO Handl Therapeutics in Leuven, Belgium, which developed gene therapy technologies, and was sold to UCB Pharma in 2020. In 2020, Florent then founded and is leading as CEO Priothera Ltd in Ireland, which is developing a late stage clinical asset in hematology. Florent is a Kaufmann Fellow (class 12) and holds a Biotechnology Engineering Master Degree from France; he did his diploma thesis on vaccines at GSK in Belgium. He also holds European and French patent lawyer degrees and a Master in Private Law.

Helene has a PhD in molecular biology during which she studied the signaling pathways activated in response to chemotherapeutic treatments in cancer cells. She also completed a master's degree in management.

Job Titles:

• Chief Scientific Officer

Karine is appointed as CSO of Amyl Therapeutics at the initiation of the Company (April 2021). She is in charge of the Research and Development management, to lead internal research activities and scientific partnerships covering preclinical and development project phases. Before to join Amyl, Karine worked in the RD department of GSK Vaccines more than 20 years and held several positions as Vaccine Project Leader as well as Head of Discovery Performance Unit of the GSK RD Center based in Italy. Karine holds a PhD in Biochemistry from the Liege University, focusing her research to the field of Protein Engineering and Design as Professor Assistant during several years before to join GSK.

Job Titles:

• Financial Advisor in the Restructurings of Faraday Furure
• President and Co - Founder of Miller Buckfire & Co
• Visiting Professor at Columbia Business School

Kenneth A. Buckfire is the President and co-Founder of Miller Buckfire & Co. During his 30 year career in restructuring he has advised clients in a broad range of industries including oil & gas, oilfield services, homebuilding and real estate, merchant power, electric utilities, broadcasting, media, telephone and data services, shipping, governments and government agencies. In addition to co-founding Miller Buckf ire in 2002 (acquired by Stifel Financial in 2012), he co-founded Marblegate Asset Management in 2008 which was sold when Stifel Financial acquired Miller Buckfire in 2012. Mr. Buckfire has been the primary financial advisor in the restructurings of Faraday Furure, Attica Bank, The City of Detroit, General Growth Properties, Calpine Corporation, Level(3) Communications, Exide Technologies, Excel Shipping, Molycorp, Standard Pacific Homes, McLeod USA, ICG Communications, iPayments, PSINet, Sirius Satellite Radio, BTI Telecom, CMS Energy, CenterPoint Energy, Oncor, Optima Steel, Horizon Natural Resources, TECO Energy, Centennial Communications, Readers Digest, Advanstar, Allegheny International, Foamex, Van Camp Seafood, Walter Industries, Burnham Broadcasting, EUA Power Corporation, Dialog Corporation, Imperial Sugar, and CRIIMI MAE. He has been an advisor to the FDIC, the National Bank of Ukraine and the Bank of Greece. For The University of Michigan, Mr. Buckfire is on the Board of Advisors of the Zell-Lurie Institute at the Ross Business School, the University Music Society and the Honors College. He is on the Board of Advisors of New Mountain Capital. He is a former Trustee of the Philharmonic Symphony Society of New York, UJA-Federation of New York, the Paul & Daisy Soros Fund for New Americans and the Orpheus Orchestra. Mr. Buckf ire is currently serving on the Boards of Directors of Purdue Pharma (Chairman of the Audit and Strategic Issues Committees), Amyl Therapeutics and ProClara Biosciences. Mr. Buckfire is a Board Observer of and a founding investor in Ambiq Micro. He has been a director of seven other public and private companies. Mr. Buckfire is a Visiting Professor at Columbia Business School where he teaches a graduate course in Corporate and Government Restructuring. He has been a guest lecturer at The University of Chicago Harris School of Public Policy and at the Ross School of Business, The University of Michigan. Mr. Buckf ire received his MBA from Columbia University in 1987. He received his B.A. in Economics and Philosophy from The University of Michigan in 1980.

Valérie Calenda started her career as research scientist in Hematology and Virology at the Institut National de la Recherche Médicale (INSERM). After collaborating on a French/US research program relating to HIV at Davis University, she joined Transgene S.A., an affiliated company of Institut Mérieux, focusing on gene Therapy and immunotherapy. She then led a spin-off project in cardio-vascular therapeutic area before collaborating with a Paris based seed Venture Capital firm. Valérie also managed several biotech clinical-stage product developments within the infectious diseases and oncology disease areas, from pre-IND to Phase 2. This led her to manage both in-licensing and out-licensing activities, including global license agreement and alliance management with Hoffman La Roche, acquisition of biotech assets in Europe and in the US. Valérie joined Mérieux Développement as a Partner in January 2010 and has focused on Venture deal flow and investments, supporting more than 8 companies since 2010. She has also been actively involved in structuring and launching M2Care, an industrial accelerator for start-ups operating in the Healthcare and Nutrition sectors. Valérie received her PhD in Pharmacology from the University of Marseille. She holds a degree in Hematology and a B.Sc. in Biochemistry-Immunology from the University of Marseille. Valérie Calenda currently serves as board member of: AcuSurgical KeepMed Keranova PhysioAssist Amyl Therapeutics Proclara Biosciences M2Care Waoup